Browsing Tag
Silevertinib
1 post
Black Diamond Therapeutics reports strong early Phase 2 response for silevertinib in first-line NSCLC patients
Discover how Black Diamond Therapeutics’ silevertinib achieved a 60% response in first-line lung cancer and why its upcoming glioblastoma trial could reshape targeted oncology.